127 related articles for article (PubMed ID: 3544033)
21. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression.
Lelièvre JD; Sacre K; Adle-Biassette H; Molinier-Frenkel V; Gaulard P; Papo T
J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):24-7. PubMed ID: 15692507
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine neurotoxicity in heart transplantation.
Vázquez de Prada JA; Martín-Duran R; García-Monco C; Calvo JR; Olalla JJ; González-Vilchez F; Gutierrez JA
J Heart Transplant; 1990; 9(5):581-3. PubMed ID: 2231100
[TBL] [Abstract][Full Text] [Related]
24. Cyclosporine-associated lymphoproliferation, despite controlled cyclosporine blood concentrations, in a renal allograft recipient.
Dossetor JB; Kovithavongs T; Salkie M; Preiksaitis J
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():1021-6. PubMed ID: 2986094
[TBL] [Abstract][Full Text] [Related]
25. Renal function and blood pressure in heart transplant recipients treated with cyclosporine.
Rottembourg J; Mattei MF; Cabrol A; Leger P; Aupetit B; Beaufils H; Gluckman JC; Pavie A; Gandjbakhch I; Cabrol C
J Heart Transplant; 1985; 4(4):404-8. PubMed ID: 3916515
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
27. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporine in heart and heart-lung transplantation.
Modry DL; Oyer PE; Jamieson SW; Stinson EB; Baldwin JC; Reitz BA; Dawkins KD; McGregor CG; Hunt SA; Moran M
Can J Surg; 1985 May; 28(3):274-80, 282. PubMed ID: 3922606
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of immunosuppression in cyclosporine-treated heart transplant patients with lymphoma.
Brumbaugh J; Baldwin JC; Stinson EB; Oyer PE; Jamieson SW; Bieber CP; Henle W; Shumway NE
J Heart Transplant; 1985 May; 4(3):307-11. PubMed ID: 3039097
[TBL] [Abstract][Full Text] [Related]
30. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
[TBL] [Abstract][Full Text] [Related]
31. Kidney function in heart-lung transplant recipients: the effect of low-dosage cyclosporine therapy.
Imoto EM; Glanville AR; Baldwin JC; Theodore J
J Heart Transplant; 1987; 6(4):204-13. PubMed ID: 3117987
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine: five years' experience in cadaveric renal transplantation.
Merion RM; White DJ; Thiru S; Evans DB; Calne RY
N Engl J Med; 1984 Jan; 310(3):148-54. PubMed ID: 6361559
[TBL] [Abstract][Full Text] [Related]
33. Posttransplant lymphoproliferative disorder: intrathoracic manifestations.
Dodd GD; Ledesma-Medina J; Baron RL; Fuhrman CR
Radiology; 1992 Jul; 184(1):65-9. PubMed ID: 1609104
[TBL] [Abstract][Full Text] [Related]
34. Posttransplant lymphoproliferative disorders in transplant recipients.
Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
[TBL] [Abstract][Full Text] [Related]
35. Increased incidence of cholelithiasis in heart transplant recipients receiving cyclosporine therapy.
Spes CH; Angermann CE; Beyer RW; Schreiner J; Lehnert P; Kemkes BM; Theisen K
J Heart Transplant; 1990; 9(4):404-7. PubMed ID: 2398436
[TBL] [Abstract][Full Text] [Related]
36. Heart allograft rejection under varying immunosuppressive protocols as evaluated by endomyocardial biopsy.
Imakita M; Tazelaar HD; Billingham ME
J Heart Transplant; 1986; 5(4):279-85. PubMed ID: 3305819
[TBL] [Abstract][Full Text] [Related]
37. Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation.
Gifford G; Fay K; Jabbour A; Ma DD
Intern Med J; 2015 May; 45(5):583-6. PubMed ID: 25955465
[TBL] [Abstract][Full Text] [Related]
38. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
Pinho-Apezzato ML; Tannuri U; Tannuri AC; Mello ES; Lima F; Gibelli NE; Santos MM; Ayoub AA; Maksoud-Filho JG; Velhote MC; Silva MM; Andrade WC; Miyatani HT
Transplant Proc; 2010 Jun; 42(5):1763-8. PubMed ID: 20620519
[TBL] [Abstract][Full Text] [Related]
39. Cyclosporine nephropathy after heart and heart-lung transplantation.
Goldstein J; Thoua Y; Wellens F; Leclerc JL; Vanherweghem JL; Vereerstraeten P; Primo G; Toussaint C
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():973-81. PubMed ID: 3921960
[TBL] [Abstract][Full Text] [Related]
40. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus.
Koch DG; Christiansen L; Lazarchick J; Stuart R; Willner IR; Reuben A
Liver Transpl; 2007 Jun; 13(6):904-12. PubMed ID: 17539010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
